


BEST AVAILABLE COPY

Sheet 1 of 2



Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 11203-002001	Application No. 09/488,867
Information Disclosure Statement by Applicant (Use several sheets if necessary) <small>(37 CFR §1.98(b))</small>		Applicant Michael J. Imperiale		
		Filing Date January 21, 2000	Group Art Unit 1646 63	

U.S. Patent Documents

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
DV	AA	6,001,557	Dec. 14, 1999	Wilson et al.	435	5	
	AC	5,994,134	Nov. 30, 1999	Giroux et al.	435	403	
	AB	5,994,132	Nov. 30, 1999	Chamberlain et al.	435	369	
	AH	5,985,846	Nov. 16, 1999	Kochanek et al.	514	44	
	AG	5,981,225	Nov. 9, 1999	Kochanek et al.	435	69.1	
	AJ	5,922,576	Jul. 13, 1999	He et al.	435	91.41	
	AD	5,919,676	Jul. 6, 1999	Graham et al.	435	172.3	
	AF	5,891,690	Apr. 6, 1999	Massie	435	172.3	
	AE	5,882,877	Mar. 16, 1999	Gregory et al.	435	320.1	
	AK	5,880,102	Mar. 9, 1999	George et al.	514	44	
DV	AL	5,851,806	Dec. 22, 1998	Kovesdi et al.	435	91.41	

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
DV	AM	EP 0 978 566	Feb. 9, 2000	EPO	C12N	15/86	X
	AN	EP 0 955 373	Nov. 10, 1999	EPO	C12N	15/86	X
	AO	WO 99/53085	Oct. 21, 1999	PCT WO 0	C12N	15/86	X
	AP	WO 99/32647	Jul. 1, 1999	PCT	C12N	15/86	X
	AQ	WO 98/13510	Apr. 2, 1998	PCT	C12N	15/86	X
	AR	WO 97/32481	Sep. 12, 1997	PCT	A01N	63/00	X
DV	AS	WO 96/33280	Oct. 24, 1996	PCT WO 0	C12N	15/86	X


Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
DV	AT	Parks et al., "Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration," <u>Gene Therapy</u> , (1999) 6, 1565-1573.
DV	AU	Mayr et al., "Development of Replication-Defective Adenovirus Serotype 5 Containing the Capsid and 3C Protease Coding Regions of Foot-and-Mouth Disease Virus as a Vaccine Candidate," <u>Virology</u> 263 (1999) 496-506.

Examiner Signature D. M. H.	Date Considered 1/14/01
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

BEST AVAILABLE COPY

Sheet 2 of 2



Substitute Form PTO-1449 (Modified 8/98)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 11203-002001	Application No. 09/488,867
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Michael J. Imperiale	
		Filing Date January 21, 2000	Group Art Unit 1646 1635

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Design ID	Document
PM	AV	Nabel, "Development of optimized vectors for gene therapy," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 96, (Jan. 1999), pp. 324-326.
	AW	Gustin et al., "Encapsulation of Viral DNA Requires the Adenovirus L1 51/55-Kilodalton Protein," <u>Journal of Virology</u> (Oct. 1998) p. 7860-7870. <i>duy trinh</i>
PM	AX	Schmid et al., "Cellular components Interact with Adenovirus Type 5 Minimal DNA Packaging Domains," <u>Journal of Virology</u> (Aug. 1998) p. 6339-6347.
	AY	Alemany et al., "Complementation of helper-dependent adenoviral vectors: size effects and titer fluctuations," <u>Journal of Virological Methods</u> 68, (1997) p. 147-159.
	AZ	Schmid et al., "Bipartite Structure and Functional Independence of Adenovirus Type 5 Packaging Elements," <u>Journal of Virology</u> (May 1997) p. 3375-3384.
	BA	Fechteler et al., "The Mechanism of Adenovirus DNA Integration: Studies in a Cell-Free System," <u>Curr. Top. Microbial. Immunol.</u> (1995) 199 (Pt. 2): 109-137.
	BB	Schmid et al., "Selective Encapsulation of Adenovirus DNA," <u>Curr. Top. Microbial. Immunol.</u> (1995) 199 (Pt. 1): 67-80.
PM	BC	Grable et al., "cis and trans Requirements for the Selective Packaging of Adenovirus Type 5 DNA," <u>Journal of Virology</u> (Feb. 1992) p. 723-731.
	BC	

Examiner Signature <i>B.M. KK</i>	Date Considered <i>1/24/04</i>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	